Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a One-Week radiation course match four weeks for prostate cancer?

NCT ID NCT07830511

NEW Disease control Sponsor: Robert Förster Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether a five-fraction course of stereotactic body radiotherapy (SBRT) works as well as the standard 20-fraction radiotherapy for men who need radiation after prostate cancer surgery. The trial enrolls 206 adults and randomly assigns them to either the short SBRT course or the standard course. The main goal is to compare urinary and bowel quality of life over two years, with follow-up for up to five years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stereotactic body radiotherapy (SBRT) to the prostate bed
What this could lead to
If SBRT works as well as standard radiotherapy, men could finish treatment in about a week instead of four weeks with similar urinary and bowel side effects.
What could go wrong
The trial is still testing whether the shorter course is safe and effective. SBRT may cause more urinary or bowel problems than standard treatment, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 206 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed prostate cancer treated with radical prostatectomy (≥ 6 months since radical prostatectomy) * Indication for adjuvant or salvage radiotherapy (e.g. persisting or rising PSA, macroscopic recurrence, R1 resection, pT3b) at the discretion of the treating physician * Androgen deprivation therapy allowed at the discretion of the treating physician * WHO performance status 0-1 * Age ≥ 18 years * Indication for treatment of the locoregional lymphatic drainage at the discretion of the treating physician allowed (not mandatory) * Personally signed and dated written informed consent Exclusion Criteria: * Inability to follow the procedures of the study (e.g. due to language problems, psychological disorders, dementia) * Comorbidities which predispose to significant radiotherapy toxicities (e.g. inflammatory bowel disease), at the discretion of the treating physician * Prior radiotherapy to the intended treatment site * Presence of distant metastases (M1a is not an exclusion criterion)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer Prostate cancer (post prostatectomy) SBRT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.